Press Detail

/

PRESS RELEASE

Biotest supports a randomized multicenter controlled trial in peritonitis (PEPPER trial) with Pentaglobin^(R) lead by Aachen University

- Trial investigates personalized treatment approaches with Biotest's Pentaglobin^(R) in patients with abdominal inflammation (peritonitis)

- Novel testing systems included to determine individual patient risks

Dreieich, 5 December 2017. Today, the first patient was enrolled in the PEPPER trial. Biotest supports the trial on personalized medicine with Pentaglobin^(R) after control of the inflammation source in peritonitis patients (PEPPER trial). It is designed to investigate in 200 patients strategies to personalize immuno-modulating approaches in patients with postoperative secondary peritonitis. With an overall mortality of more than 30%, peritonitis is one of the most fatal diseases on intensive care units.

Prof Gernot Marx from the Aachen University (RWTH Aachen), the coordinating investigator of the study mentioned "Sepsis or even peritonitis with an abdominal focus is such a heterogeneous syndrome that new and more individualized treatments are needed. An aim of the study is to identify which patient needs which kind of treatment with the immuno-modulatory substance Pentaglobin^(R). Currently we only have well established antibiotics and surgical interventions to combat the disastrous systemic infections and subsequent inflammation. Personalized treatments to normalize the immune response and to overcome the inflammatory dysregulation are urgently needed."

The subgroups identified in the PEPPER trial will enable physicians to better understand how to use immuno-modulatory treatment in this particular patient group. Results from this trial can be an important step towards a more personalized and hence successful treatment of peritonitis. The trial has been approved by the Ethics Committee at Aachen University and by Paul Ehrlich Institute (PEI) in Germany.

Further partners in the trial are Curetis GmbH for molecular diagnostic analysis and Sphingotec GmbH for the determination of additional diagnostic parameters.

About Pentaglobin^(R)
Pentaglobin^(R) is the first and only IgM-enriched immunoglobulin preparation for intravenous use. Pentaglobin^(R) significantly increases the survival rate of patients with severe bacterial infections and acts against a broad spectrum of bacterial pathogens. Pentaglobin's^(R) mode of action, is both anti-bacterial by fast neutralization of bacterial endo- and exotoxins and anti-inflammatory by scavenging excessively activated complement factors. Pentaglobin^(R) is licensed in several countries, mainly for the treatment of severe bacterial infections in combination with antibiotics.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

IR contact
Dr. Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.